A notable advancement in glucose treatment is emerging with the approval of tirzepatide at a dosage of 45mg. This updated version builds upon the existing success of tirzepatide, a dual GIP and GLP-1 receptor, and https://hannasdjs968788.actoblog.com/41692642/significant-development-tirzepatide-dose-for-blood-sugar-control